Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 16/20 | 0.46 |
| ▸ | RAB9A | P51151 | 16/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19270380 | 0.83 | ABL1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270397 | 0.81 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270403 | 0.80 | RAB9A (0.71) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270362 | 0.79 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270363 | 0.78 | MAPT (0.50) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270384 | 0.78 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270382 | 0.77 | CASP3 (0.64) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270374 | 0.77 | RAB9A (0.72) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270365 | 0.77 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19270373 | 0.77 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | NPC1 4242/4885RAB9A 2194/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.